The Effect of SARS-CoV-2 Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE)
Clinical Infectious Diseases · 06.10.2025 · 81 (3) · 416-426
DOI: 10.1093/cid/ciaf225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 18.06.2025. Verfasst von John J Openshaw und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: COVID-19, Reinfection, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CDC HHS, NCIRD CDC HHS, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
The clinical consequences of repeated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not clear, especially as they relate to long-term symptoms after infection. We analyzed data collected for the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) to determine whether reinfection changes the likelihood of symptoms 3–6 months after reinfection compared with the likelihood in individuals experiencing a single infection.
Methods
Individuals reporting a single SARS-CoV-2 infection or a single reinfection were included in this analysis. A positive SARS-CoV-2 test occurring ≥90 days after a first infection was considered a reinfection. Outcomes included severe fatigue (fatigue severity score ≥25) and the presence of organ system symptoms 3–6 months after the last infection.
Results
The analysis included 886 individuals, 415 (46.8%) of whom experienced reinfection. For individuals who experienced their first infections in either the pre-Delta or Delta periods, the odds of having ≥3 symptoms 3–6 months after their most recent infection was lower in those reinfected than those with a single infection (weighted adjusted odds ratio, 0.45 [95% confidence interval, .21–.95] and 0.51 [.32–.79], respectively). However, in individuals reporting their first infection during the Omicron wave, the odds of reporting ≥3 symptoms after the most recent infection was higher in those reinfected than in those with a single infection (weighted adjusted odds ratio, 1.54 [95% confidence interval, 1.02–2.34]).
Conclusions
The timing of initial infection, reinfection, and the variants involved may play important roles in longer-term clinical outcomes. Repeated infection with Omicron variants may increase the risk of long-term symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA.
- Covid Control Branch, Division of Communicable Disease Control, California Department of Public Health, Richmond, California, USA.
- Center for Outcomes Research and Evaluation, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Medicine, School of Medicine, University of California, Riverside, Riverside, California, USA.
- Department of Emergency Medicine, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Population Health and Health Disparities, University of Texas Medical Branch, Galveston, Texas, USA.
ORCID-Profile: John J Openshaw, Ji Chen, Michael Gottlieb, Kalyani McCullough, Michelle Santangelo, Kristyn Gatling, Ahamed H Idris, Lauren E Wisk, Jonathan Dyal, Ralph C Wang, Kristin L Rising, Kelli N O'Laughlin, Caitlin Malicki, Zhenqiu Lin, Erica S Spatz, Huihui Yu, Robert A Weinstein, Joann Elmore
Förderung
- CDC HHS
- NCIRD CDC HHS
- Centers for Disease Control and Prevention
- National Center of Immunization and Respiratory Diseases
Zitieren
APA
Openshaw, J. J., Chen, J., Rodriguez, R., Gottlieb, M., McCullough, K., Santangelo, M., Hill, M. J., Gatling, K., Idris, A. H., McDonald, S., Wisk, L. E., Dyal, J., Wang, R. C., Rising, K. L., Kean, E., O'Laughlin, K. N., Stephens, K. A., Malicki, C., Lin, Z., …, & Elmore, J. (2025). The Effect of SARS-CoV-2 Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE). Clinical Infectious Diseases, 81(3), 416-426. https://doi.org/10.1093/cid/ciaf225
Vancouver
Openshaw JJ, Chen J, Rodriguez R, Gottlieb M, McCullough K, Santangelo M, et al. The Effect of SARS-CoV-2 Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE). Clinical Infectious Diseases. 2025;81(3):416-426. doi:10.1093/cid/ciaf225
BibTeX
@article{Openshaw2025,
author = {Openshaw, John J and Chen, Ji and Rodriguez, Robert and Gottlieb, Michael and McCullough, Kalyani and Santangelo, Michelle and Hill, Mandy J and Gatling, Kristyn and Idris, Ahamed H and McDonald, Samuel and Wisk, Lauren E and Dyal, Jonathan and Wang, Ralph C and Rising, Kristin L and Kean, Efrat and O'Laughlin, Kelli N and Stephens, Kari A and Malicki, Caitlin and Lin, Zhenqiu and Spatz, Erica S and Yu, Huihui and Weinstein, Robert A and Elmore, Joann},
title = {The Effect of SARS-CoV-2 Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE)},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {3},
pages = {416--426},
doi = {10.1093/cid/ciaf225}
}
EUVIMED